2024
Dissecting the association between gut microbiota, body mass index and specific depressive symptoms: a mediation Mendelian randomisation study
Yu T, Chen C, Yang Y, Wang M, Yang Y, Feng W, Yuan S, Ma X, Li J, Zhang B. Dissecting the association between gut microbiota, body mass index and specific depressive symptoms: a mediation Mendelian randomisation study. General Psychiatry 2024, 37: e101412. PMID: 38975363, PMCID: PMC11227829, DOI: 10.1136/gpsych-2023-101412.Peer-Reviewed Original ResearchActinobacteria phylumGut microbiotaBody mass indexSpecific depressive symptomsDepressive symptomsMendelian randomisationGenome-wide association studiesTwo-sample Mendelian randomisationMass indexDepressed moodAppetite changesMendelian randomisation studiesBifidobacteriaceae familyAssociation studiesActinobacteriaPhylumMR analysisGenusFamily XIMicrobiotaObservational studyMediation analysisClinical practiceGutProtective effectGhrelin and depressive symptoms in patients with first‐episode drug‐naïve major depressive disorder: The mediating role of hypothalamic‐pituitary‐adrenal axis
Zhang C, Dong Y, Li S, Li M, Gao Y, Liu Y, Liu X, Zhou C, Li J. Ghrelin and depressive symptoms in patients with first‐episode drug‐naïve major depressive disorder: The mediating role of hypothalamic‐pituitary‐adrenal axis. Asia-Pacific Psychiatry 2024, 16: e12552. PMID: 38348641, DOI: 10.1111/appy.12552.Peer-Reviewed Original ResearchConceptsFirst-episode drug-naive MDD patientsMajor depressive disorderHAMD total scoreDrug-naive MDD patientsMDD patientsDepressive symptomsCorticotropin-releasing-hormoneTotal scoreDepressive disorderPathogenesis of major depressive disorderMeasures of depressive symptomsHealthy controlsHypothalamic-pituitary-adrenal axisHamilton Depression ScaleBody mass indexAdrenocorticotropic hormoneHAMD-17Plasma levels of ghrelinGhrelin levelsMediation analysisHAMDPartial correlation analysisDepression ScaleCortisol levelsLevels of ghrelin
2023
Associations between metabolic disorders and sleep disturbance in patients with schizophrenia
Yan H, Huang Z, Lu Y, Qiu Y, Li M, Li J. Associations between metabolic disorders and sleep disturbance in patients with schizophrenia. Comprehensive Psychiatry 2023, 122: 152369. PMID: 36702060, DOI: 10.1016/j.comppsych.2023.152369.Peer-Reviewed Original ResearchConceptsPositive and Negative Symptom ScaleSubjective sleep qualitySleep disturbanceSleep latencyPittsburgh Sleep Quality IndexSleep qualityNegative Symptom ScaleDuration of illnessLonger sleep latencySchizophrenia patientsDrug-naiveRate of MDSchizophreniaAssociated with MDSymptom ScaleMental illnessSleep Quality IndexTotal scorePartial correlation analysisImprove sleep qualityMetabolic disordersDevelopment of MDPredictors of MDBody mass indexClinical correlates
2021
The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial
Li M, Liu Y, Qiu Y, Zhang J, Zhang Y, Zhao Y, Jia Q, Li J. The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial. Psychiatry Research 2021, 300: 113899. PMID: 33812218, DOI: 10.1016/j.psychres.2021.113899.Peer-Reviewed Original ResearchConceptsAdjunctive treatmentNon-psychiatric patientsDouble-blindSerum prolactin concentrationsPlacebo-controlled clinical trialSchizophreniaMetabolic disturbancesGlycolipid metabolic parametersBaseline body mass indexImprove metabolic disturbancesLow-density lipoprotein cholesterolProlactin concentrationsSixty-five patientsFasting serum insulinWeek 8Body mass indexEffects of berberineLipoprotein cholesterolMass indexPlaceboWeek 4Previous studiesClinical trialsMetabolic parametersTotal cholesterol